{"doi":"10.1093/ofid/ofaf639","title":"Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>Factors associated with weight change were examined in phase 3 studies in which adults living with HIV-1 continued or switched to doravirine-based antiretroviral regimens.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Participants were randomized to first-line therapy with doravirine or darunavir/ritonavir, each given with 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) (DRIVE-FORWARD) and to doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) or efavirenz/emtricitabine/TDF (DRIVE-AHEAD); after 96 weeks, participants continued (n = 466) or switched to (n = 423) doravirine for 96-week open-label extensions. In DRIVE-SHIFT, virologically suppressed participants on stable antiretroviral therapy were randomized to switch to doravirine/lamivudine/TDF at day 1 or week 24 through week 144 (n = 535). Generalized logistic models were used to analyze factors associated with weight loss (≥5% decrease), stable weight (&amp;lt;5% change), and weight gain (≥5% increase) after continuation or switch.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>Most participants who continued or switched to doravirine also received TDF (&amp;gt;74%) and had stable weight (&amp;gt;57%). Weight loss (odds ratio [OR], 6.14) or stable weight (OR, 2.15) was more common in participants of non-Black versus Black heritage after switching to doravirine. More participants switching from weight-suppressive non-nucleoside reverse transcriptase inhibitors versus protease inhibitors experienced weight gain versus weight loss in DRIVE-SHIFT (OR, 0.41) and weight gain versus stable weight in DRIVE-FORWARD and DRIVE-AHEAD (OR, 0.60). No significant association between weight change and prior NRTI use was observed in DRIVE-SHIFT.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Overall, switching to doravirine was weight neutral, although weight change may differ by demographics and weight-suppressive properties of a prior regimen. More research in historically underrepresented groups may help explain these findings.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov</jats:title>\n                    <jats:p>NCT02275780, NCT02403674, NCT02397096.</jats:p>\n                  </jats:sec>","journal":"Open Forum Infectious Diseases","year":2025,"id":648361,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":240259,"name":"John R. Koethe","orcid":"0000-0001-6490-6942","position":1,"is_corresponding":false},{"id":1689630,"name":"Princy N Kumar","orcid":null,"position":2,"is_corresponding":false},{"id":1689631,"name":"Peter Sklar","orcid":"0009-0000-7071-6942","position":3,"is_corresponding":false},{"id":1689634,"name":"Zhi Jin Xu","orcid":null,"position":4,"is_corresponding":false},{"id":1689636,"name":"Rebeca M Plank","orcid":"0009-0009-4976-0792","position":5,"is_corresponding":false},{"id":1689640,"name":"Wayne Greaves","orcid":null,"position":6,"is_corresponding":false},{"id":1689642,"name":"Rima Lahoulou","orcid":null,"position":7,"is_corresponding":false},{"id":634068,"name":"Chloe Orkin","orcid":"0000-0001-6168-6745","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>Factors associated with weight change were examined in phase 3 studies in which adults living with HIV-1 continued or switched to doravirine-based antiretroviral regimens.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>Participants were randomized to first-line therapy with doravirine or darunavir/ritonavir, each given with 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) (DRIVE-FORWARD) and to doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) or efavirenz/emtricitabine/TDF (DRIVE-AHEAD); after 96 weeks, participants continued (n = 466) or switched to (n = 423) doravirine for 96-week open-label extensions. In DRIVE-SHIFT, virologically suppressed participants on stable antiretroviral therapy were randomized to switch to doravirine/lamivudine/TDF at day 1 or week 24 through week 144 (n = 535). Generalized logistic models were used to analyze factors associated with weight loss (≥5% decrease), stable weight (&amp;lt;5% change), and weight gain (≥5% increase) after continuation or switch.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>Most participants who continued or switched to doravirine also received TDF (&amp;gt;74%) and had stable weight (&amp;gt;57%). Weight loss (odds ratio [OR], 6.14) or stable weight (OR, 2.15) was more common in participants of non-Black versus Black heritage after switching to doravirine. More participants switching from weight-suppressive non-nucleoside reverse transcriptase inhibitors versus protease inhibitors experienced weight gain versus weight loss in DRIVE-SHIFT (OR, 0.41) and weight gain versus stable weight in DRIVE-FORWARD and DRIVE-AHEAD (OR, 0.60). No significant association between weight change and prior NRTI use was observed in DRIVE-SHIFT.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Overall, switching to doravirine was weight neutral, although weight change may differ by demographics and weight-suppressive properties of a prior regimen. More research in historically underrepresented groups may help explain these findings.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov</jats:title>\n                    <jats:p>NCT02275780, NCT02403674, NCT02397096.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41280318","pmcid":"PMC12631767","openalex_id":"https://openalex.org/W4416415339","authors":[],"funders":[],"total_grants":0,"fwci":1.3648,"citation_percentile":0.85342391,"influential_citations":0,"citation_trend":[{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://academic.oup.com/ofid/article-pdf/12/11/ofaf639/65407315/ofaf639.pdf","host_type":"journal"},{"url":"https://academic.oup.com/ofid/article-pdf/12/11/ofaf639/65407315/ofaf639.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/ofid/ofaf639","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41280318","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12631767","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12631767","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12631767?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["HIV-related health complications and treatments","HIV/AIDS drug development and treatment","Viral gastroenteritis research and epidemiology"],"mesh_terms":[],"keywords":["Regimen","Weight change","Weight loss","Body weight","Weight gain","MEDLINE","HIV-1","Weight","Demographics","Switch","Doravirine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T02:32:08.914486Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}